Huang Z L, Kagoshima M, Kagawa E, Shimada H
Department of Clinical Pharmacology, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
Zhongguo Yao Li Xue Bao. 1995 Mar;16(2):117-20.
To investigate if identical bioavailability, rapid Tmax, and Cmax of indometacin (Ind) could be achieved when Ind is administered in rats via intranasal (ina) route.
The pharmacokinetics of Ind solution at a dosage of 3 mg.kg-1 was studied after i.v., ina, and po in rats using HPLC.
It showed that the time to peak (Tmax) of ina Ind 3 mg.kg-1 solution was 0.08 h, approached that after i.v. route the peak concentration (Cmax) following ina was 20.0 mg.L-1, 2.4 times higher than po dosing.
It demonstrated that the ina administration of Ind was superior to po in rats, and that Ind absorption through nasal mucosa was a reasonable approach at lower doses.
研究吲哚美辛（Ind）经鼻内（ina）途径给予大鼠时，是否能实现与静脉注射相同的生物利用度、快速的达峰时间（Tmax）和峰浓度（Cmax）。
采用高效液相色谱法（HPLC）研究了大鼠静脉注射（i.v.）、经鼻内（ina）和口服（po）给予3 mg·kg-1剂量的Ind溶液后的药代动力学。
结果显示，3 mg·kg-1剂量的ina Ind溶液的达峰时间（Tmax）为0.08小时，接近静脉注射后的达峰时间；ina给药后的峰浓度（Cmax）为20.0 mg·L-1，比口服给药高2.4倍。
结果表明，在大鼠中，ina给予Ind优于po给药，且低剂量时通过鼻黏膜吸收Ind是一种合理的途径。
